Brought to you by 
Incyte agrees to acquire Synteni in all stock transaction
13 Jul 1999
Executive Summary
In an all stock transaction, Incyte Pharmaceuticals has agreed to acquire 3-year-old genomics company Synteni. Based on Incyte's closing price of $40 a share on December 29th, the transaction is worth about $88mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Incyte agrees to acquire Synteni in all stock transaction
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice